Shares of Endo Health Solutions Inc. (NASDAQ: ENDP), a specialty healthcare solutions company focusing on branded and generic pharmaceuticals, devices and services, have surged in trading today after the company agreed to acquire Canada-based Paladin Labs for approximately $1.6 billion. The acquisition will allow ENDP to expand in Canada and emerging markets. Rajiv De Silva, President and CEO of Endo Health Solutions, said that the acquisition of Paladin Labs accelerates ENDP’s transformation from an integrated health solutions company to a top tier global specialty healthcare leader. De Silva further said that Paladin Labs has a proven track record of acquiring and in-licensing innovative new products, and developing international growth platforms. At last check, ENDP shares were up 22.82% to $53.60 in pre-market trading.